Company: INMB
Filing Date: 2025-10-03
Form Type: PRE 14A
Source: 0001213900-25-096059
Chunk: 11

Company: Inmune Bio, Inc.
Filing Date: 2025-10-03
Form: PRE 14A
Chunk 11
---
 preliminary results and, within four (4) business days after the final results are known to us, file an amendment to the Form 8 -Kto publish the final results. 6

PROPOSAL 1 — APPROVAL OF REPRICING OF CERTAIN OUTSTANDING STOCK OPTIONS Overview In order to address employee retention and competitiveness concerns, we are seeking stockholder approval to reprice certain outstanding stock options granted to our current directors, executive officers and employees under the 2017 Plan, the 2019 Plan and the 2021 Plan (the “Option Pricing Proposal”). The stock options being considered for the repricing were granted between January 1, 2018 and January 22, 2025 (collectively, the “Eligible Options”). Under the Option Pricing Proposal, the exercise price per share of all Eligible Options would be reduced to an amount equal to the closing price of our common stock on the Nasdaq Capital Market on the date of the Special Meeting. We refer to the action of reducing the exercise price as the “Repricing.” All other terms and conditions of the Eligible Options, including the applicable vesting schedules, remain in force and unchanged. The Board of Directors has determined that the Repricing is in our best interest and in the best interest of our stockholders. We have historically granted stock options and other equity -basedawards under the 2017 Plan, 2019 Plan and the 2021 Plan consistent with the view that stock -basedincentive compensation opportunities play a key role in our ability to recruit, motivate and retain qualified individuals. While our compensation packages generally include a number of different components, we believe equity compensation most effectively links pay to performance as it encourages employees, directors and executive officers to work toward our success and aligns their interests with those of our stockholders by providing such employees, directors and executive officers with a means to benefit from increased stock value. We face significant competition for experienced and talented personnel with critical and high demand skills in our industry, and stock options are an important part of our incentive compensation. Additionally for certain directors, officers and employees, the Board of Directors has determined that it would be desirable to also make such individuals whole in recognition of their past service to us. As a clinical -stagepharmaceutical company, the market price for our common stock has historically been volatile, reflecting the risks and uncertainties inherent in the development of our product candidates. The Board of Directors determined that adverse changes in the market price of our common stock compared to